GetTopicDetailResponse(id=361f296867a, topicName=全身性重癥肌無(wú)力, introduction=全身性重癥肌無(wú)力, content=null, image=null, comments=5, allHits=1199, url=https://h5.medsci.cn/topic?id=29686, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=99882, tagList=[TagDto(tagId=99882, tagName=全身性重癥肌無(wú)力)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1957386, encodeId=65c0195e38608, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重癥肌無(wú)力#</a>, objectTitle=JNNP:厄瓜利珠單抗與利妥昔單抗治療全身性重癥肌無(wú)力的比較, objectType=article, longId=300333, objectId=438830033364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=438830033364, replyNumber=0, likeNumber=121, createdTime=2023-01-08, rootId=0, userName=12498cb5m13暫無(wú)昵稱(chēng), userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=438830033364, moduleTitle=JNNP:厄瓜利珠單抗與利妥昔單抗治療全身性重癥肌無(wú)力的比較, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=438830033364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957385, encodeId=6a1f195e385bb, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重癥肌無(wú)力#</a>, objectTitle=FDA 批準(zhǔn)Vyvgart 治療全身性重癥肌無(wú)力, objectType=article, longId=292400, objectId=0146292400bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0146292400bd, replyNumber=0, likeNumber=85, createdTime=2022-10-24, rootId=0, userName=12498cb5m13暫無(wú)昵稱(chēng), userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0146292400bd, moduleTitle=FDA 批準(zhǔn)Vyvgart 治療全身性重癥肌無(wú)力, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0146292400bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957383, encodeId=1519195e3831c, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重癥肌無(wú)力#</a>, objectTitle=JAMA Neurol：Zillucoplan用于治療中重度全身性重癥肌無(wú)力, objectType=article, longId=188393, objectId=6b1e188393a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1e188393a7, replyNumber=0, likeNumber=90, createdTime=2020-08-27, rootId=0, userName=12498cb5m13暫無(wú)昵稱(chēng), userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1e188393a7, moduleTitle=JAMA Neurol：Zillucoplan用于治療中重度全身性重癥肌無(wú)力, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6b1e188393a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957384, encodeId=e2e1195e3842d, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重癥肌無(wú)力#</a>, objectTitle=JAMA Neurol：利妥昔單抗治療新發(fā)全身性重癥肌無(wú)力, objectType=article, longId=193615, objectId=8cad19361569, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cad19361569, replyNumber=0, likeNumber=95, createdTime=2020-07-15, rootId=0, userName=12498cb5m13暫無(wú)昵稱(chēng), userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cad19361569, moduleTitle=JAMA Neurol：利妥昔單抗治療新發(fā)全身性重癥肌無(wú)力, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8cad19361569)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957382, encodeId=e78b195e382bd, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重癥肌無(wú)力#</a>, objectTitle=Lancet Neurol：依庫(kù)珠單抗治療抗乙酰膽堿受體抗體陽(yáng)性難治性全身性重癥肌無(wú)力III期臨床研究, objectType=article, longId=117236, objectId=41dc11e236e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41dc11e236e9, replyNumber=0, likeNumber=105, createdTime=2018-04-02, rootId=0, userName=12498cb5m13暫無(wú)昵稱(chēng), userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41dc11e236e9, moduleTitle=Lancet Neurol：依庫(kù)珠單抗治療抗乙酰膽堿受體抗體陽(yáng)性難治性全身性重癥肌無(wú)力III期臨床研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=41dc11e236e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話(huà)題小助手
2020-05-29
